Global Epithelioid Sarcoma Treatment Market - 2024-2031

Overview

The global epithelioid sarcoma treatment market reached US$ 1.32 billion in 2023 and is expected to reach US$ 2.66 billion by 2031 growing with a CAGR of 9.1% during the forecast period 2024-2031.

Epithelioid sarcoma is a rare type of cancer that starts as a growth of cells in the soft tissue and is characterized by the loss of function of the SMARCB1/INI 1 (integrase interactor 1) gene. Epithelioid sarcoma usually develops in the distal limbs like fingers, hands, forearms, and feet of young adults as a small, soft mass or a series of bumps.

Epithelioid sarcoma is generally classified into two types namely distal type and proximal type. Epithelioid sarcoma can affect people of all ages but it is more common in young adults. The global epithelioid sarcoma treatment market has witnessed significant growth in recent years due to the adoption of combination therapy treatments.

Market Dynamics: Drivers

Increasing research and developments and rising approvals of drugs for epithelioid sarcoma treatment

The demand for the global epithelioid sarcoma market is driven by multiple factors. Epithelioid sarcoma is a rare soft tissue sarcoma (which includes more than 50 subtypes) that accounts for approximately 1% of all adult cancers. Epithelioid sarcoma accounts for about 1% of all soft tissue sarcomas every year in the U.S. In 2022, research studies stated that there are fewer than 1,000 people in the U.S. who currently have ES.

The global epithelioid sarcoma treatment market has witnessed significant growth due to various recent research and developments and the rising number of clinical trials would propel this market growth. For instance, in July 2023, F. Hoffmann-La Roche announced that the Atezolizumab drug is under clinical development and is currently in Phase II for poorly differentiated chordoma, epithelioid sarcoma, and other sarcomas.

In addition, key players in the industry launched new product approvals to drive this market growth. For instance, in July 2022, HUTCHMED Limited announces that TAZVERIK (tazemetostat) was approved to be used in the Hainan pilot zone in China. For the treatment of certain patients with epithelioid sarcoma and follicular lymphoma consistent with the label as approved by the U.S. Food and Drug Administration.

Restraints

Factors such as the high cost of the treatment, side effects associated with the treatment, recurrence of the disease, lack of awareness among individuals, availability of limited treatment options, and lack of targeted therapies are expected to hamper the market.

Segment Analysis

The global epithelioid sarcoma treatment market is segmented based on type, treatment, end users, and region.

The combination therapy segment accounted for approximately 56.5% of the global epithelioid sarcoma treatment market share

The combination therapy segment is expected to hold the largest market share over the forecast period. Combination therapy is a treatment modality that combines two or more therapeutic agents to treat tumors. These therapies can combine two or more drugs or different types of therapy such as immunotherapy, chemotherapy, and radiotherapy. Combining immunotherapy with radiation could be a promising treatment option for patients with advanced soft tissue sarcoma.

The combination of irinotecan, vincristine, and the tyrosine kinase inhibitor (TKI) anlotinib is an effective regimen option for patients with metastatic or unresectable epithelioid sarcoma. According to the Memorial Sloan Kettering Cancer Center news release in February 2024, epigenetic combination therapy could overcome treatment resistance in epithelioid sarcomas and rhabdoid tumors.

Moreover, the rising clinical trials and ongoing research studies in combination therapy have contributed to the growing demand for epithelioid sarcoma treatment. For instance, according to clinicalTrials.gov, in June 2023, Dana-Farber Cancer Institute conducted a clinical trial on Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children with INI1-Negative or SMARCA4-Deficient Tumors.

This study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, and other tumors that are deficient in one of two possible proteins.

Also, in February 2024, an NCBI research publication stated that combining nanoparticle albumin-bound paclitaxel with Camrelizumab in advanced soft tissue sarcoma. Nab-paclitaxel plus Camrelizumab exhibited modest activity and mild toxicity in treating epithelioid sarcoma, angiosarcoma, and fibrosarcoma.

Geographical Analysis

North America accounted for approximately 43.2% of the global epithelioid sarcoma market share

North America region is expected to hold the largest market share over the forecast period owing to factors such as the rising prevalence of soft tissue sarcoma, increasing research and developments, and technological advancements in epithelioid sarcoma treatment would drive this market growth.

According to the American Cancer Society, the estimation for soft tissue sarcomas in the United States for 2023 is around 13,400 new soft tissue sarcomas that will be diagnosed (7,400 in males and 6,000 in females) and about 5,140 people are expected to die of soft tissue sarcomas.

Moreover, a well-advanced healthcare system and funding initiatives for the development of treatment for epithelioid sarcoma would drive this market growth in this region. For instance, in April 2024, Sarcoma UK announced almost £300,000 in funding for two research projects to improve the diagnosis and treatment of two ultra-rare sarcoma cancers.

The first project funding, totaling £149,990, has been awarded to the Institute of Cancer Research to explore epithelioid sarcoma (EPS). This is a very rare sarcoma - an average of 19 cases are diagnosed every year in England - and its cause is unknown. It can occur anywhere throughout the body but most often occurs in the hands, arms, feet, and legs. EPS is very challenging to treat with standard drugs used for sarcoma which sadly means that outcomes are poor for many patients.

Market Segmentation

By Type

• Distal Type
• Proximal Type

By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy
• Combination Therapy
• Targeted Drug Therapy
• Others

By End Users

• Hospitals
• Oncology centers
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the epithelioid sarcoma market include Ipsen, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., Baxter International, Teva Pharmaceuticals, Eisai Co. Ltd., Signa Healthcare, and Taiho Pharmaceuticals among others.

Key Developments

• In February 2024, Fred Hutch's Dr. Taran Gujral just launched TRACER, the Transformative Rare Cancer Initiative, with a $2.5 million grant from the U.S. Food & Drug Administration. This initiative aims to accelerate advances through multidisciplinary collaboration and innovative approaches.
• In August 2023, according to findings from the phase 2 Pembrolizumab trial, the PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-rare sarcoma types including chordoma and epithelioid sarcoma.
• In July 2023, SARC (Sarcoma Alliance for Research Through Collaboration) launched a national virtual multidisciplinary tumor board for sarcoma, representing nearly 20% of childhood cancers and 1% of adult cancers.
• In June 2022, Ipsen and Epizyme announced that they had entered into a definitive merger agreement under which Ipsen would acquire Epizyme. The primary focus of the acquisition is on the lead medicine, Tazverik (tazemetostat) which is a first-in-class chemotherapy EZH2 inhibitor. It is indicated for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma.

Why Purchase the Report?

• To visualize the global epithelioid sarcoma treatment market segmentation based on the type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global epithelioid sarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global epithelioid sarcoma treatment market report would provide approximately 69 tables, 70 figures, and 183 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies